Koch K, Senn M, Steingross W
Steroids. 1976 Oct;28(4):467-80. doi: 10.1016/0039-128x(76)90016-7.
In the urine of normal subjects who were given an oral dose of 500 mg spironolactone (3-(3-oxo-7alpha-acetylthio-17beta-hydroxy-4-androsten-17alpha-yl)-propionic acid gamma-lactone; Aldactone) together with 100uCi H-20, 21 spironolactone, a so far unknown major metabolite has been detected by thin layer chromatography. The metabolite then could be isolated by means of counter-current-distribution. According to masspectral and magnetic resonance data, the metabolite has been assigned the structure of 3-(3-oxo-7alpha-methyl sulfonyl-6beta, 17beta-dihydroxy-4-androsten-17alpha-yl)-propionic acid gamma-lactone. By oxidation of the corresponding methylsulfinyl compound - another already known metabolite of spironolactone - with m-chloroperbenzoic acid, a compound has been isolated which proved to be identical with the new metabolite according to TLC, MS and NMR.
在口服500毫克螺内酯(3-(3-氧代-7α-乙酰硫基-17β-羟基-4-雄甾烯-17α-基)-丙酸γ-内酯;安体舒通)并同时给予100微居里H-20的正常受试者尿液中,通过薄层色谱法检测到一种迄今未知的主要代谢产物。然后可通过逆流分配法分离该代谢产物。根据质谱和磁共振数据,该代谢产物被确定为3-(3-氧代-7α-甲基磺酰基-6β,17β-二羟基-4-雄甾烯-17α-基)-丙酸γ-内酯的结构。通过用间氯过苯甲酸氧化相应的甲亚砜基化合物(螺内酯的另一种已知代谢产物),分离出一种化合物,根据薄层色谱法、质谱和核磁共振,该化合物被证明与新代谢产物相同。